2,2-diethylpentanoyl chloride | 13023-65-9

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 酰卤
• 英文名称: 2,2-diethylpentanoyl chloride
• 英文别名: 2,2-diethyl-valeryl chloride；2,2-Diaethyl-valerylchlorid；2,2-diethylvaleryl chloride
• CAS: 13023-65-9
• 化学式: C₉H₁₇ClO
• 分子量: 176.686
• InChiKey: CVURREQGLOFEIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,2-diethylpentanoyl chloride 在 palladium on activated charcoal 、 肉桂酸乙酯 、 水 、 sodium carbonate 、 苯 作用下， 生成 1-(1,1-diethyl-butyl)-6,7-dimethoxy-isoquinoline
  参考文献：
  名称：

  Murayama, Chemical and pharmaceutical bulletin, 1958, vol. 6, p. 186,190

  摘要：

  DOI：
• 作为产物：
  描述：

  2-乙基丁腈 在 盐酸 、 氯化亚砜 、 亚硝酸丁酯 、 硫酸 、 sodium amide 、 溶剂黄146 、 甲苯 作用下， 生成 2,2-diethylpentanoyl chloride
  参考文献：
  名称：

  Murayama, Chemical and pharmaceutical bulletin, 1958, vol. 6, p. 186,190

  摘要：

  DOI：

文献信息

• Hexahydronaphthalene ester derivatives, their preparation and their
  申请人：Sankyo Company, Limited

  公开号：US05451688A1

  公开（公告）日：1995-09-19

  Compounds of formula (I): ##STR1## [wherein R.sup.1 represents a group of formula (II) or (III): ##STR2## R.sup.2 is alkyl, alkenyl or alkynyl; R.sup.3 and R.sup.4 are each hydrogen, alkyl, alkenyl or alkynyl; R.sup.5 is hydrogen or a carboxy-protecting group; R.sup.a is hydrogen or a group of formula and --OR.sup.6 ; R.sup.6, R.sup.6a and R.sup.6b are each hydrogen, a hydroxy-protecting group, alkyl, alkanesulfonyl, halogenated alkanesulfonyl or arylsulfonyl] and their salts and esters have the ability to inhibit the synthesis of cholesterol, and can thus be used for the treatment and prophylaxis of hypercholesterolemia and of various cardiac disorders.

  化合物的化学式（I）：##STR1## [其中R.sup.1代表化学式（II）或（III）的基团：##STR2## R.sup.2是烷基，烯基或炔基；R.sup.3和R.sup.4分别是氢，烷基，烯基或炔基；R.sup.5是氢或羧基保护基团；R.sup.a是氢或化学式和--OR.sup.6的基团；R.sup.6，R.sup.6a和R.sup.6b分别是氢，羟基保护基团，烷基，烷烷基磺酰基，卤代烷烷基磺酰基或芳基磺酰基]及其盐和酯具有抑制胆固醇合成的能力，因此可用于治疗和预防高胆固醇血症和各种心脏疾病。
• Hexanhydronaphthalene ester derivatives, their preparation and their therapeutic uses
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0605230A1

  公开（公告）日：1994-07-06

  Compounds of formula (I): [wherein R1 represents a group of formula (II) or (III): R2 is alkyl, alkenyl or alkynyl ; R3 and R4 are each hydrogen, alkyl, alkenyl or alkynyl ; R5 is hydrogen or a carboxy-protecting group ; Ra is hydrogen or a group of formula and -OR6 ; R6, R6a and R6b are each hydrogen, a hydroxy-protecting group, alkyl, alkanesulphonyl, halogenated alkanesulphonyl or arylsulphonyl] and their salts and esters have the ability to inhibit the synthesis of cholesterol, and can thus be used for the treatment and prophylaxis of hypercholesterolemia and of various cardiac disorders.

  式(I)化合物： [其中 R1 代表式 (II) 或 (III) 的基团： R2 是烷基、烯基或炔基；R3 和 R4 分别是氢、烷基、烯基或炔基；R5 是氢或羧基保护基团；Ra 是氢或式和 -OR6 的基团；R6、R6a 和 R6b 分别为氢、羟基保护基团、烷基、烷磺酰基、卤代烷磺酰基或芳基磺酰基]及其盐和酯具有抑制胆固醇合成的能力，因此可用于治疗和预防高胆固醇血症和各种心脏疾病。
• Synthesis of novel 5-piperidyl-substituted 7-hydroxy-3H-1,2,3-triazolo[4,5-d]pyrimidines
  作者：K. V. Kuleshov、K. Yu. Borovkov、O. G. Rodin、V. P. Perevalov

  DOI：10.1007/s10593-006-0078-2

  日期：2006.2
• 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side-chain ester derivatives of mevinolin
  作者：W. F. Hoffman、A. W. Alberts、P. S. Anderson、J. S. Chen、R. L. Smith、A. K. Willard

  DOI：10.1021/jm00155a040

  日期：1986.5

  Modification of the 2(S)-methylbutyryl moiety of mevinolin led to a series of side chain ester derivatives. A systematic exploration of the structure-activity relationships showed that the introduction of an additional aliphatic group on the carbon alpha to the carbonyl group increased potency. This observation led to the synthesis of compound 16, which has about 2.5 times the intrinsic inhibitory activity of mevinolin.
• Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0605230B1

  公开（公告）日：1997-08-27